Hansoh Pharmaceutical Group Company Limited (3692.HK)
HKD 24.4
(1.24%)
HKD 24.4
(1.24%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 7.24 Billion CNY | -1.5% |
| 2022 | 7.35 Billion CNY | 3.14% |
| 2021 | 7.13 Billion CNY | 144.52% |
| 2020 | 2.91 Billion CNY | -55.34% |
| 2019 | 6.53 Billion CNY | -3.53% |
| 2018 | 6.76 Billion CNY | 315.96% |
| 2017 | 1.62 Billion CNY | -21.09% |
| 2016 | 2.06 Billion CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.76 Billion CNY | 0.0% |
| 2023 Q2 | 7.76 Billion CNY | 0.0% |
| 2023 Q4 | 7.24 Billion CNY | 0.0% |
| 2023 FY | 7.24 Billion CNY | -1.5% |
| 2022 Q4 | 7.35 Billion CNY | 0.0% |
| 2022 FY | 7.35 Billion CNY | 3.14% |
| 2022 Q2 | 7.71 Billion CNY | 0.0% |
| 2021 Q4 | 7.13 Billion CNY | 0.0% |
| 2021 FY | 7.13 Billion CNY | 144.52% |
| 2021 Q2 | 6.9 Billion CNY | 0.0% |
| 2020 FY | 2.91 Billion CNY | -55.34% |
| 2020 Q4 | 2.91 Billion CNY | 0.0% |
| 2020 Q2 | 4.45 Billion CNY | 0.0% |
| 2019 FY | 6.53 Billion CNY | -3.53% |
| 2019 Q4 | 6.53 Billion CNY | 0.0% |
| 2019 Q2 | 5.77 Billion CNY | 0.0% |
| 2018 FY | 6.76 Billion CNY | 315.96% |
| 2018 Q3 | 6.77 Billion CNY | 0.0% |
| 2018 Q4 | 6.76 Billion CNY | -0.12% |
| 2017 FY | 1.62 Billion CNY | -21.09% |
| 2016 FY | 2.06 Billion CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 142.28 Million HKD | -4991.513% |
| Grand Pharmaceutical Group Limited | 7.24 Billion HKD | 0.007% |
| Extrawell Pharmaceutical Holdings Limited | 170.4 Million HKD | -4151.179% |
| Wai Yuen Tong Medicine Holdings Limited | 709.65 Million HKD | -920.822% |
| Qianhai Health Holdings Limited | 94 Million HKD | -7606.463% |
| Lee's Pharmaceutical Holdings Limited | 930.06 Million HKD | -678.9% |
| Essex Bio-Technology Limited | 903.78 Million HKD | -701.555% |
| Tongfang Kontafarma Holdings Limited | 665.38 Million HKD | -988.732% |
| PuraPharm Corporation Limited | 689.65 Million HKD | -950.431% |
| SSY Group Limited | 4.49 Billion HKD | -61.202% |
| JBM (Healthcare) Limited | 366.75 Million HKD | -1875.255% |
| Jacobson Pharma Corporation Limited | 1.09 Billion HKD | -564.314% |
| China Resources Pharmaceutical Group Limited | 168.46 Billion HKD | 95.7% |